Welcome to the first edition of our European Healthcare & Life Sciences Market Update, a new report summarising key emerging trends, opportunities, and challenges facing the market in 2022. During the last 12 months, the...more
2/10/2022
/ Clinical Trials ,
Digital Health ,
EU ,
EU Clinical Trials Regulation (CTR) ,
Health Care Providers ,
Joint Venture ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Regulatory Agenda ,
Regulatory Standards ,
UK ,
Venture Capital
The healthcare and life sciences (HCLS) sector remained particularly active throughout 2020. Despite the COVID-19 pandemic, deal activity was very strong in the first half of the year — with notable transactions including...more
1/28/2021
/ Acquisitions ,
Compliance ,
Coronavirus/COVID-19 ,
Cross-Border Transactions ,
Cybersecurity ,
Divestment ,
Emerging Markets ,
Health Care Providers ,
Health Technology ,
Healthcare Facilities ,
Hospitals ,
Industry Consolidation ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Physicians ,
Private Equity
The guidance provides helpful clarity on key regulatory changes impacting life sciences companies in the event of a no-deal Brexit.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published a...more
4/4/2019
/ Article 50 Treaty of the EU ,
EU ,
European Economic Area (EEA) ,
Health Care Providers ,
Healthcare ,
Life Sciences ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
New Guidance ,
New Legislation ,
No-Deal Brexit ,
Pharmaceutical Industry ,
Time Extensions ,
UK ,
UK Brexit ,
Withdrawal Agreement